ClinPGx Blog (Page 24)

Sign in Subscribe

More issues

Congratulations to Dr. Teri Klein!

PharmGKB is pleased to announce that the Stanford Provost has approved Dr. Teri Klein’s appointment as a Professor of Biomedical Data Science! This appointment is effective March 1 and represents a great acknowledgement of Teri’s academic contributions and leadership in data science and pharmacogenomics. Teri and Russ Altman

CPIC Guideline Update: CYP2C9/VKORC1/CYP4F2 and Warfarin

The 2017 update of CPIC guideline for pharmacogenetics-guided warfarin dosing has been accepted for publication in Clinical Pharmacology and Therapeutics. CPIC extensively reviewed the literature up to Dec 2016. Both the dosing recommendations and supplemental information were updated. The accepted article can currently be viewed on the PharmGKB and

New PharmGKB pathway: macrolide antibiotics pharmacokinetics/pharmacodynamics

The PharmGKB summary of the pharmacokinetics and pharmacodynamics of macrolide antibiotics has been published in Pharmacogenetics and Genomics. This summary introduces the candidate genes involved in the pharmacokinetic and pharmacodynamic pathways of macrolide antibiotics, focusing on erythromycin, clarithromycin, and azithromycin. We present the uptake, transport, metabolism and clearance of the

CPIC Guideline Summary Videos Available on PharmGKB

A new resource is available on PharmGKB to help researchers and clinicians more easily and quickly understand CPIC recommendations and how to find supporting information on the PharmGKB website. Short ~5 minute videos describe the role of the gene(s) and the impact of genetic variation on drug response, provide

Early Registration for Precision Medicine Conference ends Sunday

Early registration for the University of Florida Precision Medicine Conference, held from March 8-10 in Orlando, Florida, ends this Sunday, January 22 at midnight. Earn continuing education credit and learn how to translate pharmacogenomics into practice. The program, which includes speakers, case studies, and participant genotyping, will provide practical

CPIC Guideline Update: CYP2D6, CYP2C19 and tricyclic antidepressants (TCAs)

The 2016 update of the guidelines by the Clinical Pharmacogenetics Implementation Consortium (CPIC) regarding the use of pharmacogenetic tests for CYP2D6 and CYP2C19 in dosing tricyclic antidepressants (TCAs) have been accepted for publication in Clinical Pharmacology and Therapeutics. The accepted article can currently be viewed on the PharmGKB and CPIC

New CPIC Guideline - CYP2C19 and voriconazole

Guidelines by the Clinical Pharmacogenetics Implementation Consortium (CPIC) regarding the use of pharmacogenetic tests of CYP2C19 for voriconazole prescribing decisions have been accepted for publication in Clinical Pharmacology and Therapeutics. The accepted article can currently be viewed on the PharmGKB or CPIC websites. Voriconazole is a triazole antifungal agent active

New and Updated PMDA label translations now available

New translations of package inserts from the Pharmaceutical and Medical Devices Agency (PMDA), Japan, as well as updated translations of existing package inserts, are now available on PharmGKB. The PMDA is a regulatory agency responsible for scientific reviews for the approval of drugs or medical devices, as well as safety

Very Important Pharmacogene (VIP) summary for MT-RNR1 published in Pharmacogenetics and Genomics

The PharmGKB review of the MT-RNR1 gene has been published in the December issue of Pharmacogenetics and Genomics. MT-RNR1 is a mitochondrial gene that codes for ribosomal RNA (rRNA). Variations within this gene, particularly rs267606617 (1555A>G), are strongly associated with the development of hearing loss following

Upcoming change to user accounts

We will be making a small change to user accounts this weekend that should make our users’ lives a little easier. Registered PharmGKB users will no longer be required to have a username as part of their profile. Instead, users will be able to log into the site and manage